Contact
QR code for the current URL

Story Box-ID: 214184

Roche Diagnostics Deutschland GmbH Sandhofer Str. 116 68309 Mannheim, Germany http://www.roche.de/
Contact Mr Dr. Burkhard Ziebolz +49 8856 604830
Company logo of Roche Diagnostics Deutschland GmbH
Roche Diagnostics Deutschland GmbH

Roche Diagnostics Licenses Rights to Use SYBR Green in Real Time PCR to Exiqon

(PresseBox) (Penzberg, )
Roche Diagnostics and Exiqon A/S, Vedbæk, Denmark, a provider of high-value gene expression analysis products, announced that they have entered into a license agreement for use of SYBR Green reagent in PCR. Under the terms of the agreement, Exiqon obtains from Roche a non-exclusive license to use SYBR Green I in Real Time PCR. SYBR Green provides the simplest and most economical format for detecting and quantitating PCR products in Real-Time PCR reactions. Financial terms of the agreement were not disclosed.

"From our view, the licensing of the use of SYBR Green reagent in Real Time PCR reaction is an important contribution to further developing the PCR technology in the life science field," states Manfred Baier, Head of Roche Applied Science, a business area of Roche Diagnostics.

Roche and Exiqon signed an amendment to their 2005 license and distribution agreement for Exiqon's Universal ProbeLibrary (UPL) already some weeks ago.

Roche Diagnostics Deutschland GmbH

Headquartered in Basel, Switzerland, Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As the world's biggest biotech company and an innovator of products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people's health and quality of life. Roche is the world leader in in-vitro diagnostics and drugs for cancer and transplantation, and is a market leader in virology. It is also active in other major therapeutic areas such as autoimmune diseases, inflammatory and metabolic disorders and diseases of the central nervous system. In 2007 sales by the Pharmaceuticals Division totaled 36.8 billion Swiss francs, and the Diagnostics Division posted sales of 9.3 billion francs. Roche has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai, and invested over 8 billion Swiss francs in R&D in 2007. Worldwide, the Group employs about 80,000 people. Additional information is available on the Internet at www.roche.com.

The publisher indicated in each case (see company info by clicking on image/title or company info in the right-hand column) is solely responsible for the stories above, the event or job offer shown and for the image and audio material displayed. As a rule, the publisher is also the author of the texts and the attached image, audio and information material. The use of information published here is generally free of charge for personal information and editorial processing. Please clarify any copyright issues with the stated publisher before further use. In case of publication, please send a specimen copy to service@pressebox.de.
Important note:

Systematic data storage as well as the use of even parts of this database are only permitted with the written consent of unn | UNITED NEWS NETWORK GmbH.

unn | UNITED NEWS NETWORK GmbH 2002–2024, All rights reserved

The publisher indicated in each case (see company info by clicking on image/title or company info in the right-hand column) is solely responsible for the stories above, the event or job offer shown and for the image and audio material displayed. As a rule, the publisher is also the author of the texts and the attached image, audio and information material. The use of information published here is generally free of charge for personal information and editorial processing. Please clarify any copyright issues with the stated publisher before further use. In case of publication, please send a specimen copy to service@pressebox.de.